562 related articles for article (PubMed ID: 28714960)
1. BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer.
Wang J; Jia Y; Zhao S; Zhang X; Wang X; Han X; Wang Y; Ma M; Shi J; Liu L
Oncogene; 2017 Nov; 36(45):6235-6243. PubMed ID: 28714960
[TBL] [Abstract][Full Text] [Related]
2. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
3. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
4. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
5. Tanshinone IIA induces ER stress and JNK activation to inhibit tumor growth and enhance anti-PD-1 immunotherapy in non-small cell lung cancer.
Zhang YZ; Lai HL; Huang C; Jiang ZB; Yan HX; Wang XR; Xie C; Huang JM; Ren WK; Li JX; Zhai ZR; Yao XJ; Wu QB; Leung EL
Phytomedicine; 2024 Jun; 128():155431. PubMed ID: 38537440
[TBL] [Abstract][Full Text] [Related]
6. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor-1α and nuclear factor-κB play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small-cell lung cancer cells.
Guo R; Li Y; Wang Z; Bai H; Duan J; Wang S; Wang L; Wang J
Cancer Sci; 2019 May; 110(5):1665-1675. PubMed ID: 30844110
[TBL] [Abstract][Full Text] [Related]
8. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
[TBL] [Abstract][Full Text] [Related]
9. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
Ren S; Tian Q; Amar N; Yu H; Rivard CJ; Caldwell C; Ng TL; Tu M; Liu Y; Gao D; Ellison K; Suda K; Rozeboom L; Rivalland G; Mitchell P; Zhou C; Hirsch FR
Lung Cancer; 2018 Nov; 125():115-120. PubMed ID: 30429008
[TBL] [Abstract][Full Text] [Related]
10. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
11. MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer.
Bouillez A; Rajabi H; Jin C; Samur M; Tagde A; Alam M; Hiraki M; Maeda T; Hu X; Adeegbe D; Kharbanda S; Wong KK; Kufe D
Oncogene; 2017 Jul; 36(28):4037-4046. PubMed ID: 28288138
[TBL] [Abstract][Full Text] [Related]
12. Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma.
Del C Monroig-Bosque P; Driver B; Morales-Rosado JA; Deavers M; Tacha D; Bernicker E; Cagle PT; Miller RA
Arch Pathol Lab Med; 2018 Nov; 142(11):1388-1393. PubMed ID: 29431467
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic Insights of Anti-Immune Evasion by Nobiletin through Regulating miR-197/STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer (NSCLC) Cells.
Sp N; Kang DY; Lee JM; Jang KJ
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576006
[TBL] [Abstract][Full Text] [Related]
14. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
Peng S; Wang R; Zhang X; Ma Y; Zhong L; Li K; Nishiyama A; Arai S; Yano S; Wang W
Mol Cancer; 2019 Nov; 18(1):165. PubMed ID: 31747941
[TBL] [Abstract][Full Text] [Related]
15. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
16. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer.
Wang S; Xu L; Che X; Li C; Xu L; Hou K; Fan Y; Wen T; Qu X; Liu Y
FEBS Lett; 2018 Feb; 592(4):621-630. PubMed ID: 29364514
[TBL] [Abstract][Full Text] [Related]
17. MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
Kim EY; Kim A; Kim SK; Chang YS
Lung Cancer; 2017 Aug; 110():63-67. PubMed ID: 28676221
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC.
Bassanelli M; Sioletic S; Martini M; Giacinti S; Viterbo A; Staddon A; Liberati F; Ceribelli A
Anticancer Res; 2018 Jul; 38(7):3789-3796. PubMed ID: 29970498
[TBL] [Abstract][Full Text] [Related]
19. Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer.
Theelen WSME; Kuilman T; Schulze K; Zou W; Krijgsman O; Peters DDGC; Cornelissen S; Monkhorst K; Sarma P; Sumiyoshi T; Amler LC; Willems SM; Blaauwgeers JLG; van Noesel CJM; Peeper DS; van den Heuvel MM; Kowanetz M
PLoS One; 2019; 14(5):e0216864. PubMed ID: 31125352
[TBL] [Abstract][Full Text] [Related]
20. B7-1 and programmed cell death-ligand 1 in primary and lymph node metastasis lesions of non-small cell lung carcinoma.
Yamada T; Miki Y; Suzuki M; Kondoh O; Saito-Koyama R; Ono K; Okada Y; Sasano H
Cancer Med; 2022 Jan; 11(2):479-491. PubMed ID: 34907653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
